FutureChemistry

What FutureChemistry does

FutureChemistry Holding BV is a privately held boutique consultancy headquartered in Wageningen, the Netherlands, founded in 2007 and operating with fewer than 10 staff plus a three-member advisory board. The firm industrializes radiochemical and radiopharmaceutical innovations, supporting radiopharmaceutical developers, medical isotope producers, and pharmaceutical companies entering nuclear medicine across Europe. Its service portfolio spans four integrated lines: custom equipment design and engineering, process development and automation, commissioning/qualification/validation, and Chemistry, Manufacturing and Controls (CMC) plus Quality Assurance strategy. The company's flagship proprietary product is the CISSPECT Desk-Lab, a modular automated radiopharmaceutical synthesiser for controlled chemical synthesis.

Underlying the service offering is deep expertise in flow chemistry applied to radiochemical and radiopharmaceutical production, with a particular emphasis on translating bench-scale reactions into automated, cGMP-aligned processes. The team is composed of PhD-level radiochemists and an industry veteran CMC/GMP consultant (formerly in senior QA roles at Bayer), giving the firm regulatory-grade credibility. The firm is ISO 9001 certified, operates independently of any equipment manufacturer, and uniquely does not assert claims on client-developed intellectual property — a positioning feature for risk-averse buyers in a regulated industry.

FutureChemistry generates revenue primarily through professional-services engagements (consultancy, process development, validation, CMC/QA), supplemented by custom hardware/equipment builds and sales of the CISSPECT Desk-Lab platform. Go-to-market is sales-led and event-driven: the CEO maintains an active LinkedIn presence, the firm attends industry conferences such as EANM 2025 in Barcelona, and a free, obligation-free initial consultation serves as the lead-conversion mechanism. No external funding rounds or institutional investors have been disclosed.

Name

FutureChemistry

Legal name

FutureChemistry Holding BV

Website

https://futurechemistry.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

FutureChemistry is a Netherlands-based boutique consultancy that industrializes radiopharmaceutical and medical isotope production processes, serving European drug developers and isotope producers with custom equipment design, automation, validation, and CMC/QA services.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Process Consulting

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)

Keywords

• Radiopharmaceutical consultancy
• Process development services
• Flow chemistry equipment
• CGMP compliance services
• Radiopharmaceutical manufacturing

Headquarters

HQ city

Wageningen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Consultancy Services: Boutique consultancy providing expertise in designing and building equipment, validating processes, and developing quality strategies in the radiopharmaceutical industry. Revenue derived from professional consulting engagements.
2. Equipment Design and Engineering: Custom equipment design and build services for radiopharmaceutical processes, including systems for medical isotope purification and radiopharmaceutical manufacturing.
3. CMC and QA Services: Broad spectrum of Chemistry, Manufacturing and Controls services from equipment and process design to technology transfer and manufacturing support for clinical trials.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

FutureChemistry is a boutique consultancy specializing in developing equipment, processes, and quality strategies in the radiopharmaceutical industry. The company provides custom solutions spanning from concept to clinic, including equipment design and engineering, process development and automation, commissioning and validation, and CMC & QA services for radiopharmaceutical and medical isotope production. Its core physical product is the CISSPECT Desk-Lab, a modular automated radiopharmaceutical synthesiser.

Product overview

FutureChemistry is a boutique consultancy specialising in the radiopharmaceutical industry, offering an integrated portfolio of services spanning equipment design and engineering, process development and automation, commissioning and validation, and CMC and QA services. The company provides the Cisspect Desk-Lab automated radiopharmaceutical synthesiser as its core product, alongside custom engineering solutions for medical isotope purification and radiopharmaceutical manufacturing. All services are designed to advance radiochemical and radiopharmaceutical innovations from concept to clinic, supporting clients throughout Europe.

Differentiator

Problem solved

Functional benefit

Products and services

• CISSPECT Desk-Lab Modular automated chemical synthesis system (automated radiopharmaceutical synthesiser) designed for radiopharmaceutical production processes. It enables controlled chemical synthesis of radiopharmaceuticals and serves radiopharmaceutical manufacturers and researchers.
• Equipment Design and Engineering Custom equipment design and engineering services for radiopharmaceutical processes, including systems for purification of medical isotopes and manufacturing of radiopharmaceuticals. Designed and built based on individual client needs.
• Process Development and Automation Development of new processes and automation of existing processes for radiopharmaceutical manufacturing, maximising efficiency and reliability. Targets radiopharmaceutical companies and medical isotope producers.
• Commissioning, Validation and Documentation Commissioning, qualification, and validation services ensuring smooth implementation of radiopharmaceutical processes. Supports clients through documentation and regulatory readiness.
• CMC & QA Services Chemistry, Manufacturing and Controls strategy services supporting cGMP-compliant operations for medical isotopes and radiopharmaceuticals. Covers equipment and process design, technology transfer, and manufacturing support for clinical trials.

Quantifiable outcome

• Advancing radiochemical and radiopharmaceutical innovations from concept to clinic

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• VU University Medical CentrecoreStrategic or Co-development PartnerDion van der Born performed PhD research at VU University Medical Centre, developing novel methodology for incorporating fluorine-18 labelled trifluoromethyl functional groups onto aromates. This represents a foundational research partnership for the company's radiochemistry expertise.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Trasis: Belgium-based company specializing in automated synthesis modules and quality control equipment for radiopharmaceutical production. Direct peer as both design and supply hardware/software solutions for radiochemistry synthesis and purification, serving the same radiopharma and medical isotope customer base across Europe.
• Raytest: Germany-based specialist in radio-TLC, radio-HPLC, and radiochemistry measurement instruments for PET and radiopharmaceutical applications. Closely comparable as a focused instrumentation and tools provider for radiochemistry workflows, serving overlapping customers in European research institutes and radiopharma companies.

Broad incumbents

• GE HealthCare (Radiopharma Solutions): Global medical technology incumbent offering integrated radiopharma manufacturing equipment, CDMO services, and isotope production across PET and SPECT modalities. Broad incumbent overlapping with FutureChemistry in custom equipment design and GMP-compliant radiopharma process development, but at vastly greater scale.
• Siemens Healthineers (PETNET Solutions): Operates one of the largest radiopharma manufacturing networks globally, offering PET tracer production and distribution services. Overlaps with FutureChemistry in process industrialization and GMP-compliant manufacturing, but as part of a much larger diagnostics and imaging portfolio.
• IBA Radiopharma Solutions: Belgian-listed company providing cyclotrons, integrated PET radiopharma solutions, and contract manufacturing. Comparable to FutureChemistry in custom radiochemistry equipment and process development, but with significantly greater capital and global reach.
• Eckert & Ziegler: German-based radiopharma services and isotope production company offering contract manufacturing, equipment, and radioisotope distribution. Overlaps with FutureChemistry in radiopharmaceutical process equipment and GMP-compliant production services, but at substantially larger scale.
• Curium Pharma: Global radiopharmaceutical CDMO and manufacturer serving diagnostic and therapeutic nuclear medicine markets. Comparable as a GMP-compliant contract manufacturer for radiopharmaceuticals, but at vastly greater scale and as part of integrated commercial manufacturing rather than boutique consulting.
• Advanced Accelerator Applications (Novartis): Novartis-owned radioligand therapy pioneer (Lutathera, Pluvicto) with extensive manufacturing infrastructure for therapeutic radiopharmaceuticals. Overlaps with FutureChemistry in process industrialization and GMP manufacturing, but as part of a global pharma-backed operation.

Emerging players

• Comecer: Italian manufacturer of shielded cells, hot cells, and radiopharmaceutical manufacturing isolators. Comparable as a European supplier of specialized equipment for radiopharmaceutical production, though more focused on shielding/infrastructure than synthesis automation like FutureChemistry.
• Tema Sinergie: Italian supplier of radiochemistry synthesis modules, dose calibrators, and radiopharma production equipment. Closely comparable niche player providing automated synthesis systems for PET and therapeutic radiopharmaceuticals, targeting similar European customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/futurechemistry
• LinkedInlinkedin.com/company/futurechemistry

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FutureChemistry